Veracyte (VCYT) Earns Media Sentiment Score of 0.28
Press coverage about Veracyte (NASDAQ:VCYT) has been trending positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7633132699206 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Veracyte Inc (VCYT) Shares Sold by Broadfin Capital LLC (americanbankingnews.com)
- Zacks: Analysts Anticipate Veracyte Inc (VCYT) Will Announce Quarterly Sales of $19.08 Million (americanbankingnews.com)
- Piper Jaffray Companies Reiterates Hold Rating for Veracyte (VCYT) (americanbankingnews.com)
- Veracyte Inc to Host Earnings Call (finance.yahoo.com)
- Veracyte Q4 Earnings Preview (finance.yahoo.com)
Veracyte (VCYT) traded up $0.05 during midday trading on Friday, hitting $5.98. The stock had a trading volume of 121,011 shares, compared to its average volume of 107,211. The company has a market cap of $205.06, a PE ratio of -6.57 and a beta of 1.61. Veracyte has a 12 month low of $5.23 and a 12 month high of $9.80. The company has a quick ratio of 4.86, a current ratio of 4.49 and a debt-to-equity ratio of 0.68.
COPYRIGHT VIOLATION WARNING: “Veracyte (VCYT) Earns Media Sentiment Score of 0.28” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/03/04/veracyte-vcyt-earns-media-sentiment-score-of-0-28.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.